Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

CRISPR Therapeutics (CRSP), having achieved success with its ex vivo gene therapy Casgevy, is now focusing on in vivo candidates, with initial data from its CTX310 study showing dose-dependent decreases of up to 82% in triglycerides and 81% in LDL; CTX320 data is expected in Q2 2025. Despite this progress, CRISPR Therapeutics lags behind Intellia Therapeutics (NTLA) in clinical-stage in vivo programs, and faces competition from Beam Therapeutics (BEAM), while its shares have underperformed the industry year-to-date and its loss per share estimates for 2025 and 2026 have widened.

Analysis

CRISPR Therapeutics (CRSP) has successfully commercialized Casgevy, a CRISPR-based ex vivo gene therapy developed with Vertex Pharmaceuticals, and is now strategically pivoting to its in vivo pipeline. Promising initial top-line data from the Phase I study of its in vivo candidate CTX310, targeting ANGPTL3 for atherosclerotic heart disease, demonstrated dose-dependent reductions in low-density lipoprotein (LDL) and triglyceride (TG) levels by up to 81% and 82% respectively. The company anticipates a data readout for another in vivo candidate, CTX320 targeting Lp(a), in the second quarter of 2025 and plans to advance two additional in vivo programs into clinical trials by year-end, signaling an expansion of its efforts in this emerging modality. However, CRSP faces significant competition, notably from Intellia Therapeutics (NTLA), which is advancing two candidates, NTLA-2002 and nex-z, through late-stage development and plans an FDA regulatory filing for its HAE therapy next year, positioning it as a front-runner in the in vivo space. Beam Therapeutics (BEAM) also presents competition with its differentiated base-editing in vivo candidates, BEAM-302 and BEAM-301, currently in Phase I/II studies. Financially, CRSP shares have underperformed the industry year-to-date and trade at a price-to-book ratio of 1.80, considerably lower than the industry average of 3.10 and its own five-year mean of 2.41. Compounding these concerns, consensus loss per share estimates for CRSP have widened for both 2025 (from $4.96 to $5.54) and 2026 (from $3.65 to $4.11) over the past 60 days, reflecting increased investor caution despite its scientific advancements.

Key Decisions for Investors

• Investors should closely monitor CRISPR Therapeutics' execution on its in vivo pipeline milestones, particularly the CTX320 data readout expected in Q2 2025, while critically assessing its competitive positioning relative to leaders like Intellia Therapeutics.
• The current valuation discount, with a price-to-book ratio of 1.80 compared to the industry's 3.10, must be carefully weighed against the financial risks highlighted by widening loss per share estimates for 2025 and 2026 and the stock's recent underperformance.
• Consider the progress of the two additional in vivo programs planned for clinical entry by year-end as key indicators of pipeline depth, alongside the company's ability to navigate an increasingly competitive gene-editing landscape to achieve market differentiation.